Kirjaudu sisään Inderes Free -tilillesi nähdäksesi kaikki sivun maksuton sisältö.
Carasent
23,6
SEK
0 %
CARA
NASDAQ Stockholm
Medical Equipment & Services
Health Care
1 671 seuraajaa
0%
+9,77%
+6,31%
+26,27%
+38,24%
+125,22%
−20,48%
+65,89%
+6,7%
Carasent is an IT company. The company delivers a wide range of products and services in communication and IT infrastructure specifically aimed at the healthcare industry. Examples of solutions include proprietary cloud-based services, email management, mobile solutions, and security solutions. Customers are mainly found in health and care, finance, and telecom. The company was originally established in 1997 and is headquartered in Gothenburg.
Lue lisääMarkkina-arvo
1,71 mrd. SEK
Vaihto
17,21 milj. SEK
Liikevaihto
EBIT %
P/E -luku
Osinkotuotto %
Pörssikalenteri
11.4.
2025
Osavuosikatsaus Q1'25
23.4.
2025
Yhtiökokous '25
10.7.
2025
Osavuosikatsaus Q2'25
NäytäKaikki sisältötyypit

Carasent, Audiocast with teleconference, Q4'24
Carasent AB (publ) – Year-end report January–December 2024
Liity Inderesin yhteisöön
Älä jää mistään paitsi – luo käyttäjätunnus ja ota kaikki hyödyt irti Inderesin palvelusta.
FREE-tili
Pörssin suosituin aamukatsaus
Analyytikon kommentit ja suositukset
Osakevertailu
PREMIUM-tili
Kaikki yhtiöraportit ja sisällöt
Premium-työkalut (mm. sisäpiirin kaupat ja screeneri)
Mallisalkku
Carasent AB (publ) – Invitation to presentation of Q4 2024 results
Carnegie Access: Carasent: We expect a solid end to the year – Q4 preview
Carasent AB (publ) announces changes to the Nomination Committee
First day of trading in Carasent AB (publ) on Nasdaq Stockholm
Carasent ASA - Mandatory notifications of trades resulting from merger of Carasent ASA into Carasent AB (publ)
Carasent ASA has completed its planned cross-border merger
Information regarding the last day of trading in Carasent ASA on Oslo Børs
Carasent AB (publ) offentliggör prospekt i samband med dess notering på Nasdaq Stockholm
Carasent AB (publ) publishes prospectus in connection with its listing on Nasdaq Stockholm
Redeye: Redeye SaaS 2024 Q3 - Positive Profitability Trend Halts
Carasent ASA - primary insider trading
Carnegie Commissioned Research: Carasent: Administering healthy growth
Carasent ASA - Carasent AB (publ) has been approved for listing on Nasdaq Stockholm
Redeye: Carasent - From On-Prem “Papierpolizei” to the Cloud
